Maxim Group Trims Kiora Pharmaceuticals (NASDAQ:KPRX) Target Price to $1.00

Kiora Pharmaceuticals (NASDAQ:KPRXGet Rating) had its target price decreased by investment analysts at Maxim Group to $1.00 in a research note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s target price indicates a potential upside of 149.94% from the company’s previous close.

Separately, HC Wainwright lowered their target price on Kiora Pharmaceuticals from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, April 19th.

Shares of NASDAQ KPRX traded up $0.02 during midday trading on Thursday, hitting $0.40. 800 shares of the stock traded hands, compared to its average volume of 410,376. The stock has a market capitalization of $5.07 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. Kiora Pharmaceuticals has a one year low of $0.35 and a one year high of $6.43. The stock has a 50-day moving average price of $0.54.

Several institutional investors have recently modified their holdings of KPRX. Geode Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals during the 4th quarter valued at $791,000. BlackRock Inc. purchased a new position in Kiora Pharmaceuticals during the fourth quarter valued at $32,000. Finally, Renaissance Technologies LLC bought a new stake in Kiora Pharmaceuticals during the first quarter valued at about $58,000. Institutional investors and hedge funds own 29.70% of the company’s stock.

About Kiora Pharmaceuticals (Get Rating)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Featured Articles

Stock Target Advisor logo

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with's FREE daily email newsletter.